Organigram Global (OGI) Capital Expenditures (2018 - 2026)
Organigram Global (OGI) posted quarterly Capital Expenditures of -$1.7 million for Q1 2026, up 62.59% year-on-year from -$1.0 million in Q1 2025, and down 12.47% on a QoQ basis from -$1.5 million in Q4 2025.
Organigram Global (OGI) Capital Expenditures (2018 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Capital Expenditures for 7 consecutive years, with -$1.7 million the latest figure, recorded in Q1 2026.
- Quarterly Capital Expenditures rose 62.59% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.9 million (down 5.35% YoY) and the FY2025 annual result came in at $12.4 million, up 256.65% from the prior year.
- Capital Expenditures slipped to -$1.7 million in Q1 2026 per OGI's latest filing, from -$1.5 million in the prior quarter.
- Over the last five years, Capital Expenditures for OGI reached as high as -$1.2 million in Q4 2024 and fell as low as -$4.5 million in Q1 2025.
- A 3-year average of -$2.2 million and a median of -$1.6 million in 2025 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2025 — Capital Expenditures declined 29.62% — and 2026, when it soared 62.59%.
- Year by year, Capital Expenditures stood at -$1.2 million in 2024, then fell by 29.62% to -$1.5 million in 2025, then dropped by 12.47% to -$1.7 million in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$1.7 million, -$1.5 million, and -$4.5 million for Q1 2026, Q4 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Organigram Global | 89.89 Mn | 122.96 Mn | 28.97 Mn | -1.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.70 Mn |
| Mar 31, 2026 | -1.70 Mn |
| Dec 31, 2025 | -1.51 Mn |
| Dec 31, 2025 | -1.51 Mn |
| Mar 31, 2025 | -4.54 Mn |
| Mar 31, 2025 | -4.54 Mn |
| Dec 31, 2024 | -1.16 Mn |
| Dec 31, 2024 | -1.16 Mn |
| May 31, 2021 | -6.38 Mn |
| May 31, 2021 | -6.38 Mn |
| Feb 28, 2021 | 3.63 Mn |
| Feb 28, 2021 | 3.63 Mn |
| Nov 30, 2020 | -1.81 Mn |
| Nov 30, 2020 | -1.81 Mn |
| Aug 31, 2020 | -9.23 Mn |
| Aug 31, 2020 | -9.23 Mn |
| May 31, 2020 | 24.65 Bn |
| May 31, 2020 | 24.65 Bn |
| Feb 29, 2020 | 64,973.00 |
| Feb 29, 2020 | 64,973.00 |